Related Experiment Videos
Abstract:
Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1). The following bacteria were isolated: P. aeruginosa: 11; Enterobacteriaceae: 10; Acinetobacter: 3; Staphylococci: 3 (including 2 methicillin-resistant strains), and Streptococcus faecalis: 2. Pefloxacin was given in a daily dosage of 800 mg in 20 patients and 1 200 to 1 600 mg in 7. All pathogens proved susceptible, in varying degrees. 21 patients recovered. Three incomplete results and three failures were observed. No significant side effects were recorded except for development of three mucosal candidiasis and two transient rashes. The authors put special emphasis on the value of pefloxacin in bone and meningeal infections.
Insights
Pefloxacin effectively treated various infections in 27 patients, showing particular value in bone and meningeal infections. Most patients recovered with minimal side effects, highlighting pefloxacin
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Microbiology
Context:
- Pefloxacin, a fluoroquinolone antibiotic, was investigated for its efficacy against a range of bacterial infections.
- The study included patients with bone and/or joint, respiratory tract, urinary tract, bacteremia, and meningeal infections.
Purpose:
- To evaluate the clinical effectiveness and safety of pefloxacin in treating diverse bacterial infections.
- To assess the susceptibility of isolated pathogens to pefloxacin.
- To highlight the potential of pefloxacin in treating specific infection types like bone and meningeal infections.
Summary:
- Twenty-seven patients received pefloxacin for various infections, with pathogens including Pseudomonas aeruginosa, Enterobacteriaceae, Acinetobacter, Staphylococci (including MRSA), and Streptococcus faecalis.
- Dosages ranged from 800 mg to 1600 mg daily. 21 patients recovered, with three incomplete results and three treatment failures.
- Minor side effects included mucosal candidiasis and transient rashes; pefloxacin demonstrated particular efficacy in bone and meningeal infections.
Impact:
- Pefloxacin demonstrated significant clinical utility in treating a spectrum of bacterial infections.
- The findings support the use of pefloxacin, especially for challenging bone and meningeal infections.
- Further research may explore optimized dosing and combination therapies involving pefloxacin.